);
Contáctanos

Autor: Inge Van Vaerenbergh

Publicado el
LinkedIn Post 1
April 2025

All eyes on Fertiga in Women’s Health during BioTrinity 2025!!

We are proud to present our innovative fertility tests at the ‘Women’s Health’ Spotlight during BioTrinity 2025 in London, UK.

BioTrinity is an event organised by OBN (UK) Ltd, that brings together the life science community, and we are proud to attend and showcase Fertiga’s innovative Aurora Test. This is a fantastic opportunity to connect, collaborate, and explore new business opportunities in the UK.

Publicado el
LinkedIn Post 1
November 2024

Fertiga presenting at ESHRE SIG Embryology Workshop!

Discover cutting-edge advancements in IVF technology, including non-invasive PGT-A, automatic vitrification, and AI-driven gamete and embryo selection at the ESHRE SIG Embryology Campus Event in Manchester, UK from 14-16 November 2024.

Don’t miss Tom Adriaenssens from Fertiga leading a hands-on session on ‘Non-invasive pregnancy prediction based on cumulus cells (AURORA-Test) in routine ART: The practical application, impact and challenges’.

Publicado el
LinkedIn Post 1
February 2024

We have been published in PLOS One!

Can we use a method that “scores” eggs based on the cells surrounding them (called cumulus cells) to pick the ones most likely to lead to a successful pregnancy? This approach can help reduce the number of embryos we need to grow in the lab and limit extra embryos being frozen.

In countries where freezing embryos is restricted, analyzing these surrounding cells allows us to focus only on the eggs with the best potential. This can reduce the chance of twins, lower the lab workload, and improve overall success rates, because less promising eggs are not processed unnecessarily.

💡Learn how our Aurora Test on cumulus cells can revolutionize embryo generation in countries with legal restrictions.

Publicado el
LinkedIn Post 1
December 2024

We are attending Belgian Society for Reproductive Medicine 2023!!

Fertiga was present at the 50th Scientific Meeting of the Belgian Society for Reproductive Medicine BSRM-Belgium in Mons on Dec 1-2. Together we explored the latest breakthroughs and shared insights with fellow experts in the field. Inspiring discussions, valuable insights and wonderful connections were made.

Publicado el
LinkedIn Post 1
December 2023

All eyes on Fertiga in HealthTech Investor Summit!

Exciting news! 🚀 Fertiga is gearing up to pitch at the Health Tech Investor Summit in Bruges from December 4th. Curious to hear our pitch? Join us in Bruges next week!

Publicado el
LinkedIn Post 1
November 2022

Fertiga’s CMO became a honorary member of BSRM!

Fertiga is very proud with the recognition of our CMO Prof. Dr. Johan Smitz as an honorary member of the Belgian Society for Reproductive Medicine during the latest Autumn meeting.

This is a well deserved acknowledgement after Prof. Smitz’ extraordinary research contribution to better understand the follicle and the oocyte development and its regulation at different stages of folliculogenesis in animal models (mouse, guinea pig, bovine, goat) and human.

Fertiga’s Aurora Test, is a direct result from Prof. Smitz’ important involvement in the development of new diagnostic technologies to predict oocyte competence for pregnancy outcomes in women undergoing IVF treatments. We are happy to be part of this and improve IVF patients’ lifes.